Background: Desmoplastic melanoma (DM) is a subvariant of spindle cell melanoma, accounting for less than 4% of all cutaneous melanomas. It occurs later in life and is associated with chronic sun exposure. Desmoplastic melanoma prognosis is considered more favorable than other variants, with lower rates of metastasis and higher survival. Recently, DM has been further subclassified into pure and mixed, calling into question surgical management and patient outcomes as well as viability of current nationwide databases without this distinction. Methods: We identified all patients with a histopathologic diagnosis of DM from the Cleveland Clinic electronic melanoma database (n = 58) from 1997 to 2013. Clinical and histopathologic data were collected. Comparison in clinical variables was performed between patients who had pure (n = 15) and mixed (n = 43) variants of DM. Results: There were no differences in age, sex, location of lesion, Breslow depth, ulceration, or regression. Patients with mixed DM were more likely to have lymphovascular invasion (P = 0.03) compared with pure DM. There was no difference in performance of sentinel lymph node biopsy (P = 0.25) or sentinel lymph node positivity (P = 0.31) between the 2 groups. Recurrence was present in 13.3% of pure and 30.2% of mixed patients. Overall, Kaplan-Meier 3-year survival was 75% for pure and 80% for mixed DM (P = 0.53). Conclusions: Pure and mixed DMs seem to have similar clinical characteristics and outcomes. This indicates that analysis of national datasets without this subclassification remains viable.
D
esmoplastic melanoma (DM) is a subvariant of spindle cell melanoma first described by Conley et al in 1971 , accounting for less than 4% of all cutaneous melanomas. [1] [2] [3] Desmoplastic melanoma occurs later in life compared with conventional melanoma, with mean age around 66 years, and predominantly affects males. 4 Etiology is uncertain; however, chronic sun exposure seems to be a risk factor. Clinical appearance varies with appearance of nodules, plaques to ill-defined scar-like lesions, which are most often amelanotic. 4 Histologically, DM is characterized by proliferation of malignant spindle cells associated with a dense collagenous stroma. There is often an overlying junctional component present.
Prognosis for patients with DM varies widely among studies. The first reports suggested that patients with DM may have poorer prognosis than patients with other types of melanomas. 5 Later reports suggested that survival was better among patients with DM than those with conventional melanoma. 6 However, estimated 5-year survival of conventional melanomas regardless of stage is 91%, whereas in DM studies, survival ranges from 67% to 89%. 1, 4, 7, 8 These survival differences have been further emphasized in recent histopathologic distinction between pure DM (pDM) and mixed DM (mDM). Pure DM lesions are characterized by at least 90% of desmoplasia, whereas mDM lesions contain less than 90% desmoplasia and a high cellular density. 9 Because of this variability, we examined patients in a single tertiary-referral center in the Midwest. In this historical cohort study, we compared recurrence rates and survival of patients diagnosed with pDM or mDM.
METHODS AND MATERIALS

Patient Sample
This study was approved by the Cleveland Clinic Institutional Board Review. We used the Cleveland Clinic melanoma database to identify all patients with histopathologic diagnosis of DM in the period from 1997 to 2013. Demographic and clinical data, including recurrence, metastasis, and death, were collected using manual search of electronic medical records. Occurrence of death was rechecked using the Social Security Death Index. Histopathologic information analysis composed of melanoma location, Breslow thickness, Clark level, ulceration, mitotic index, presence of micro-and macrosatellitosis, regression, lymphocytosis, and lymphovascular and perineural invasion. Histopathologic slides were reviewed by a board-certified dermatopathologist to establish whether melanomas were pure or mixed type. Pure DM was defined as at least 90% of desmoplasia with a paucicellularity, whereas mDM contained less than 90% desmoplasia and a high cellular density. 9 Surgical and pathologic reports were also included for sentinel lymph node biopsy (SLNB) and lymphadenectomy data. Survival was measured using overall survival.
Statistical Methods
Continuous variables were expressed as mean (SD) and compared by using the t test. Categorical variables were expressed as percentages and compared using the χ 2 or Fisher exact tests. The groups' survival rates were calculated by using the Kaplan-Meier method and compared by using log-rank test. A P < 0.05 was considered significant.
RESULTS
A total of 58 patients with DM were identified. Of these, 43 were considered mDM and 15 were pDM. There were no significant differences in age, sex, family history of melanoma, immunosuppression, and location of lesion between mDM and pDM patients (Table 1) . Mixed DM was most often located on the head and neck area, followed by the upper extremity, whereas pDM was located mostly on the trunk. Average follow-up time was 3.46 years. Breslow depth (3.51 ± 3.51 mDM vs 3.36 ± 2.63 pDM, P = 0.88), Clark level, ulceration, mitotic index, presence of micro-and macrosatellites, regression, and perineural invasion did not differ between the 2 groups (Table 2) . Patients with mDM were more likely to have lymphovascular invasion (P = 0.03, Fig. 1 ) and tended to have less lymphocytic infiltrate (P = 0.09).
Sentinel lymph node biopsy was performed in 55.8% of mDM and 73.3% of pDM patients; however, this difference was not statistically significant (P = 0.25, Fig. 2 ). There was no difference in number of sentinel lymph nodes (SLNs) removed (2.25 ± 2.11 mDM vs 2.27 ± 1.19 pDM, P = 0.97) or in sentinel node positivity (0.12 ± 0.34 mDM vs 0.33 ± 0.89 pDM, P = 0.31). Lymphadenectomy was performed in 23.3% of mDM patients and in 20% of pDM patients (P = 0.72). There was no difference in the number of nodes removed (P = 0.77) or in node positivity (n = 0.61) after lymphadenectomy between the 2 groups.
Recurrence occurred in 30% of patients with mDM and in 13.3% of patients with pDM, but this difference was not significant (P = 0.22). Average time to detection of recurrence was 3.09 years. Distant metastases developed in 18.6% of mDM and in 6.7% of pDM patients. Kaplan-Meier 3-year survival for pDM was 75% versus 80% for mDM, whereas 5-year survival was 75% and 73%, respectively (P = 0.53, Fig. 3 ). The majority of recurrences occurred within 1 year from diagnosis for pure type and 3 years for mixed type (P = 0.88).
DISCUSSION
Recently, DM was separated into pure and mixed subtypes, and little information exists on how these histopathologic differences have influenced surgical management. In this single-center cohort study, we found that there is no significant difference in the overall 3-and 5-year survival between pDM and mDM. Lymphovascular invasion was higher among mDM patients, whereas there was no difference in In addition, the number of nodes removed during lymphadenectomy and node positivity did not differ between the 2 groups. Distant metastases occurred in 18.6% of mDM and 6.6% of pDM. This study is in agreement with previous reports of male predominance in development of DM with 2.1:1 ratio, slightly lower than the Surveillance, Epidemiology and End Results Program report of 2.3:1 for mixed type of melanoma and higher than the 1.7:1 in conventional melanoma. 1, 10 This could be explained by our smaller numbers and an apparent increasing incidence trend. 1 Interestingly, among the patients with pDM, the ratio was 1:1.14, indicating more women had pDM. The mean age of patients was 64 years for mixed and 60 years for pure, both of which are younger than the previously reported 66 years and closer to the median age of conventional melanoma. 1, 4, 10 In contrast, a study comparing patients with pDM and mDM showed that those with mDM are younger than patients with pDM.
11
As in previous studies, the most common location of DM was on the head and neck area, whereas the second most common location was the upper extremity for mDM and the trunk for pDM. 2, 6, 12, 13 Similar to George et al, there was no difference between the pDM and mDM subtypes. 9 The severity of DM and predominantly sun-exposed locations are in line with previous statements of increasing occurrence with sun exposure. 1 In our patient population, Breslow thickness did not differ between the 2 groups. Similarly, in another study, there was no difference in Breslow thickness among pDM or mDM patients. 11 The majority of our patients were Clark level 4 or 5, with no difference between pDM and mDM. This was supported by George et al.
Unlike George et al, we found no statistically significant difference in mitotic index between the 2 groups. Interestingly, we also found that mDM patients were more likely to have lymphovascular invasion, which conflicts with the findings of George et al.
Sentinel lymph node biopsy use in DM has been evaluated in several studies. Reported SLN positivity for DM ranges from 0% to 12.1%, which was similar to mDM in our study; however, 18.2% of pure desmoplastic were positive. 3 In contrast, several studies found that rates of node positivity ranged between 0% and 2% among patients with pDM and between 16% and 22% for mDM.
11,14-16 Dunne et al 16 recommended SLNB for mDM but not for pDM because of previously reported low rates of SLN positivity, given the procedural complications and cost; however, we recommend considering SLNB in both types based on our results.
Rates of distant metastases among studies vary from 0% to 19%, with the older studies presenting higher numbers of distant metastasis, whereas approximately 4% of conventional melanomas have distant metastases. 1, 7, 10 The largest study examining DMs, using Surveillance, Epidemiology and End Results Program data, demonstrates a 5% distant metastasis rate. 1 A study of 280 patients in the Melanoma Unit of Australia found that there was no difference between rates of metastasis of desmoplastic and non-DMs. 2 In our study, the rate of distant metastasis was 18.6% for mDM and 6.7% for pDM, but this difference was not statistically significant.
Our survival rates are similar to the 75% 5-year survival reported by Quinn et al. 2 Interestingly, a recent article by Han et al 17 also showed a similar 5-year overall survival of 74.5% with lower limit of 95% confidence interval, 69.2%. It is possible that the lack of a difference in survival between the 2 groups could be attributed to no difference in age, Breslow thickness, ulceration, mitotic index, and perineural invasion. 1 Because of the varied behavior of DM, certain treatment modalities have also shown different effects on recurrence and survival. For example, performing SLNB has been highly questioned, with lower node positivity, and, according to a recent systematic review, sentinel node biopsy should be considered only in mDM. 16 Furthermore, treatment of DMs with wide local excision and postoperative radiation therapy had improved outcomes compared with wide local excision only and is suggested for superior local recurrence control. 18 Finally, recent reports on anti-programmed cell death/programmed cell death-ligand 1 therapy have shown a better response of metastatic DM, indicating that these patients could be better candidates for therapy. 19 Future treatment modalities may highlight additional differences in the behavior of DM.
CONCLUSIONS
Despite the histopathologic distinction in pDM and mDM, in our experience, these are biologically too similar to recommend any change in management. As such, and given the limited numbers available for study, mDM and pDM can be grouped together to assess best practices. Although distant metastases occurred in 18.6% in mDM and 6.7% in pDM, 5-year survival for both was approximately 75%. Mixed DM patients were predominantly male, whereas there was no sex difference in pure patients. There was no difference in immunosuppression and family history between pDM and mDM patients. It is interesting to note that although histopathologic differences exist, there is no difference in surgical management and overall patient survival in the DM subtypes.
